US FDA approves Lilly weight-loss drug, will compete with Novo's Wegovy
© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo)'s drug for weight loss, giving the U.S. drugmaker official entry into a lucrative market that has captured Wall Street's enthusiasm this year.
Zepbound will be available in the U.S. by the end of the year at a list price of $1,059.87, according to Lilly. That compares with a list of $1,349 per-package for Novo Nordisk - a measure of weight based on height - of at least 30, or a BMI of 27 or more if a patient also has another weight-related health issue, such as heart disease.
The Indianapolis-based drugmaker said it is launching a commercial savings card program to make Zepbound cost as little as $25 for patients whose insurance agrees to cover the drug, and $550 for those whose insurance does not. The enormous demand for new weight-loss treatments could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said earlier this year.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Weiterlesen »
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Weiterlesen »
US FDA approves Lilly weight-loss drugThe U.S. Food and Drug Administration on Wednesday approved Eli Lilly's (LLY.N) drug for weight loss, giving the U.S. drugmaker official entry into a lucrative market that has captured Wall Street's enthusiasm this year.
Weiterlesen »
FDA approves a new weight loss drug, Zepbound from Eli LillyThe medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Weiterlesen »
Eli Lilly gets FDA approval for new obesity drugZepbound helped patients lose up to 48 pounds on average in clinical trials
Weiterlesen »
Eli Lilly's Obesity Drug Gets FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Weiterlesen »